Diplomat Pharmacy, Inc. (NYSE:DPLO)’s share price gapped down prior to trading on Friday . The stock had previously closed at $21.16, but opened at $19.07. Diplomat Pharmacy shares last traded at $14.63, with a volume of 4527000 shares changing hands.
A number of brokerages recently issued reports on DPLO. Mizuho set a $16.00 target price on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research report on Tuesday, October 24th. TheStreet upgraded shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Needham & Company LLC increased their target price on shares of Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $19.39.
The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. The company has a market capitalization of $1,033.09, a PE ratio of 19.48, a PEG ratio of 2.70 and a beta of 0.74.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the company earned $0.21 EPS. Diplomat Pharmacy’s revenue was down 4.8% on a year-over-year basis. sell-side analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Diplomat Pharmacy by 73.1% in the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after acquiring an additional 3,056 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Diplomat Pharmacy by 80.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after acquiring an additional 3,833 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after acquiring an additional 2,794 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Diplomat Pharmacy in the 3rd quarter valued at about $191,000. Finally, Municipal Employees Retirement System of Michigan lifted its holdings in Diplomat Pharmacy by 4.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after acquiring an additional 480 shares during the last quarter. 66.51% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://transcriptdaily.com/2017/11/19/diplomat-pharmacy-inc-dplo-shares-gap-down-to-19-07.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.